Customised radiation after neoadjuvant chemotherapy in breast cancer
Menée à partir des données de l'étude "RAPCHEM" portant sur 838 patientes ayant reçu un traitement systémique pour un cancer du sein de stade cT1–2N1 et présentant au maximum 3 ganglions suspects, cette étude analyse l'efficacité à 10 ans d'une radiothérapie locorégionale adaptée à la réponse ganglionnaire
Although oestrogen receptor, progesterone receptor, and HER2 receptor expression status help to tailor neoadjuvant systemic therapy regimens in patients with breast cancer, the response to treatment is arguably more prognostic than is receptor status itself. The amount of residual disease following neoadjuvant therapy, as calculated by the residual cancer burden index, correlates with disease recurrence independent of stage or receptor status. In patients with high risk of recurrence based on substantial residual disease, trials such as KATHERINE and CREATE-X provide data to support escalation of adjuvant systemic therapy, providing truly personalised medicine for patients with breast cancer.
The Lancet Oncology , commentaire en libre accès, 2026